Nuvation Bio Inc.
NUVB · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.16 | -0.44 | -1.94 |
| FCF Yield | -18.26% | -20.59% | -23.19% | -4.07% |
| EV / EBITDA | -1.21 | -2.93 | -2.67 | -17.38 |
| Quality | ||||
| ROIC | -120.86% | -16.38% | -18.14% | -12.28% |
| Gross Margin | 10.10% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.23 | 0.90 | 0.92 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -91.83% | 29.45% | -40.90% | -86.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.39 | 0.81 | 1.45 |
| Interest Coverage | -1,737.91 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 427.96 | 0.00 | 0.00 | 0.00 |